A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Clinical trial NCT02495233 · TERMINATED
Trial details
- NCT number
- NCT02495233
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-08
- Primary completion
- 2016-09-28
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.